Ginsenoside Rg1 Ameliorates LPS ‐Induced Sepsis‐Associated Lung Injury in Mice via VEGFC /D‐ VEGFR3 Signaling‐Mediated Lymphangiogenesis and Lymphatic Remodeling
The Kaohsiung Journal of Medical Sciences · 07.05.2026
DOI: 10.1002/kjm2.70229 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Kaohsiung Journal of Medical Sciences, online erschienen am 07.05.2026. Verfasst von He Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infection, Beijing Friendship Hospital, Capital Medical University, Beijing, China. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China.
Themen: Sepsis
Abstract (Originalsprache)
Sepsis‐induced acute lung injury (ALI) remains challenging to treat, with conventional anti‐inflammatory therapies offering limited efficacy. The lymphatic system is crucial for removing edema and inflammatory mediators, and its impairment can exacerbate lung injury. Ginsenoside Rg1, a bioactive botanical compound, has diverse pharmacological properties, but its ability to modulate lymphangiogenesis in septic ALI is unclear. This study investigated whether Ginsenoside Rg1 can alleviate lipopolysaccharide (LPS)‐induced ALI in mice by promoting lymphangiogenesis via the vascular endothelial growth factor C (VEGFC)/D‐VEGF receptor 3 (VEGFR3) signaling pathway. ALI was induced in C57BL/6 mice by intraperitoneal injection of LPS (10 mg/kg). Mice were treated with Rg1 at low (30 mg/kg) or high (60 mg/kg) doses. Lung injury was assessed by wet‐to‐dry weight ratios, vascular permeability, histopathology, and lymphatic vessel density. Levels of inflammatory cytokines, VEGFC/D, VEGFR3, and downstream signaling molecules were measured by enzyme‐linked immunosorbent assay, western blotting, and qPCR. Ginsenoside Rg1 treatment dose‐dependently reduced pulmonary edema, vascular leakage, and histological damage. It also reversed LPS‐induced decreases in VEGFC/D and increased VEGFR3 expression, resulting in enhanced lymphatic vessel density. Rg1 activated VEGFR3 downstream pathways (ERK/Prox‐1, AKT) and upregulated lymphatic function genes ( CCL21a, ACKR2 ). Ginsenoside Rg1 can attenuate septic ALI by stimulating the VEGFC/D‐VEGFR3 axis to promote functional lymphangiogenesis, thereby facilitating clearance of edema and inflammatory mediators. This mechanism offers a novel therapeutic strategy focused on enhancing clearance rather than only on suppressing inflammation, potentially reducing tissue damage and the side effects associated with conventional treatments.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Infection, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
- Department of Occupational Medicine and Clinical Toxicology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
ORCID-Profile: He Wang, Chun-Pan Zhang
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
Zitieren
APA
Wang, H., Hu, L., Zhang, C. P., Qi, W. J., & Song, Y. G. (2026). Ginsenoside Rg1 Ameliorates LPS ‐Induced Sepsis‐Associated Lung Injury in Mice via VEGFC /D‐ VEGFR3 Signaling‐Mediated Lymphangiogenesis and Lymphatic Remodeling. The Kaohsiung Journal of Medical Sciences. https://doi.org/10.1002/kjm2.70229
Vancouver
Wang H, Hu L, Zhang CP, Qi WJ, Song YG. Ginsenoside Rg1 Ameliorates LPS ‐Induced Sepsis‐Associated Lung Injury in Mice via VEGFC /D‐ VEGFR3 Signaling‐Mediated Lymphangiogenesis and Lymphatic Remodeling. The Kaohsiung Journal of Medical Sciences. 2026. doi:10.1002/kjm2.70229
BibTeX
@article{Wang2026,
author = {Wang, He and Hu, Lan and Zhang, Chun-Pan and Qi, Wen-Jie and Song, Yu-Guo},
title = {Ginsenoside Rg1 Ameliorates LPS ‐Induced Sepsis‐Associated Lung Injury in Mice via VEGFC /D‐ VEGFR3 Signaling‐Mediated Lymphangiogenesis and Lymphatic Remodeling},
journal = {The Kaohsiung Journal of Medical Sciences},
year = {2026},
doi = {10.1002/kjm2.70229}
}
EUVIMED